Merial appoints Fabian Kausche to lead Global Research & Development

- Veteran of animal health brings depth of expertise to Merial's R&D organization -

LYON, France, June 10, 2014 /PRNewswire/ -- Merial, the animal health division of Sanofi, today announced that Fabian Kausche will be leading the company's global research and development (R&D) efforts, effective June 9, 2014. Dr. Kausche brings to the company a wide range of global experience in pharmaceutical and biological R&D and business leadership positions, at both human and animal health companies.

Dr. Kausche joins Merial after 10 years at Novartis, where he was most recently global Head of R&D for Animal Health. Prior to this, he served as Senior Vice President and global Head of R&D for the Over-The-Counter Human Health Division, and as Vice President of Sales for the US Companion Animal business, successfully increasing year-over-year sales. Before joining Novartis, he was a clinical research scientist for the Upjohn Company and senior director for clinical development of biologicals for Pfizer Animal Health.

"Fabian's expertise and proven track record in product development with approvals around the world, in addition to his business and organizational leadership, deliver a rare combination of talents and knowledge," said Carsten Hellmann, CEO of Merial "With our recent introductions of groundbreaking products like NexGard™ and Longrange®, and with an extensive pipeline in place, Fabian's leadership will further accelerate our R&D efforts for continued and sustainable growth and success."

As the new Global Head of R&D, Dr. Kausche will be based in Duluth, Ga., USA, with responsibility for advancing Merial's leadership in the discovery and development of innovative vaccines and therapies for companion and production animals. He will lead Merial's global R&D team, including more than 700 scientists and support staff at R&D sites around the world, to advance more than 50 projects currently in development for a variety of animal species.

A German citizen, Fabian holds a PhD in veterinary medicine from the Veterinary School in Hannover Germany, a Masters of Science degree from Iowa State University (US), and completed an Advanced Management Program at Harvard Business School.

Fabian Kausche will be a member of the Merial Leadership Team and will report to Merial CEO Carsten Hellmann.  He will also be a member of the Sanofi R&D Leadership Team.

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs 6,200 people and operates in more than 150 countries worldwide with close to €2 billion of sales in 2013. Merial is a Sanofi company. More info on

Media Contact: Heidi De Wit-Sommerfeld - Tel: +1 678 638 3763


Copyright (C) 2014 PR Newswire. All rights reserved

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.